HAYWARD, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and CEO, will present at the Bear Stearns 20th Annual Healthcare Conference in New York at the Grand Hyatt on Monday, September 10, 2007 at 10:30 a.m. Eastern Time. A live webcast of the presentation can be accessed through http://cc.talkpoint.com/BEAR002/091007a_sc/?entity=kosan.
Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentation will be available for two weeks.
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiple
pathways involved in cancer cell growth and survival. Tanespimycin
(KOS-953) is being tested in combination with bortezomib in patients with
multiple myeloma in a registration program called TIME. Tanespimycin is
also being studied in HER2-positive metastatic breast cancer in combination
with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and
oral formulations of Kosan's second-generation Hsp90 inhibitor,
alvespimycin (KOS-1022), ar
|SOURCE Kosan Biosciences Incorporated|
Copyright©2007 PR Newswire.
All rights reserved